Original studyA controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm
References (29)
- et al.
Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension
Am J Cardiol
(1992) - et al.
Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset
Am J Cardiol
(1989) - et al.
The value of class 1C antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm
J Am Coll Cardiol
(1990) - et al.
Randomized placebo-controlled trial of propafenone for treatment of atrial tachyarrhythmias after cardiac surgery
J Am Coll Cardiol
(1987) - et al.
Intravenous administration of propafenone [letter]
J Am Coll Cardiol
(1992) - et al.
Management of patients with atrial fibrillation
Am J Med
(1964) - et al.
Termination of acute atrial fibrillation in the Wolff-Parkinson-White syndrome by procainamide and propafenone: importance of atrial fibrillatory cycle length
J Am Coll Cardiol
(1990) - et al.
Possible atrial proarrhythmic effects of class 1C antiarrhythmic drugs
Am J Cardiol
(1990) The hazards of using type 1C antiarrhythmic drugs for the treatment of paroxysmal atrial fibrillation
Am J Cardiol
(1990)- et al.
Atrial flutter in patients treated for atrial fibrillation with propafenone
Am J Cardiol
(1990)
The present status of therapy of the cardiac arrhythmias with quinidine
Am Heart J
Episodic drug treatment in the management of paroxysmal arrhythmias
Am J Cardiol
Epidemiologic features of chronic atrial fibrillation. The Framingham study
N Engl J Med
Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized double-blinded trial
Ann Intern Med
Cited by (114)
“Pill in the Pocket” Antiarrhythmic Drugs for Orally Administered Pharmacologic Cardioversion of Atrial Fibrillation
2021, American Journal of CardiologyCitation Excerpt :More recently, the class IC AADs, flecainide, and propafenone, have supplanted quinidine compounds for oral PITP therapy. Both of these agents have been given in more consistent protocols and have generally produced more rapid and higher rates of conversion and better tolerance than quinidine, sotalol, amiodarone, procainamide, and placebo.2,7,9,12,20–34 However, populations studied have had more specific exclusion criteria (see later) than in some of the quinidine studies.
Single High Oral Dose Amiodarone for Cardioversion of Recent Onset Atrial Fibrillation
2012, Heart Lung and Circulation2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society
2011, Journal of the American College of CardiologyPharmacologic Conversion of Atrial Fibrillation and Atrial Flutter
2010, Cardiac Electrophysiology ClinicsCitation Excerpt :Intravenous propafenone was superior in the first hour of observation (rate of conversion 48% vs 15% of oral propafenone), whereas the overall efficacy of oral administered propafenone was superior at 8 hours (78% vs 53% of intravenous propafenone).48 Oral propafenone was as efficacious as oral flecainide31 and superior both to oral amiodarone50 and quinidine plus digoxin within the first 4 hours,51 although this superiority was lost after a longer periods of observation (>6 hours). Currently used dosages for intravenous administration are 1.5 to 2.0 mg/kg over 10 to 20 minutes, followed by 0.007 mg/kg/min infusion.
Bayesian Network Meta-analysis of Randomized Controlled Trials on the Efficacy of Antiarrhythmics in the Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation
2023, American Journal of Cardiovascular Drugs